We haven’t investigated the tumor tissue, but we believe that a novelty of our study stems from having compared the circulating BCR repertoire of melanoma patients treated with immunotherapy in a neoadjuvant clinical setting, which should maximize the chances of retrieval for these biologics. This evidence concerns the gene BCR and melanoma.